Presentation at the Molecular Medicine Tri-Conference to Highlight Clinical Performance of Trovagene's Precision Cancer Monitoring Platform

Ultra-high sensitivity drives clinical applications and pharmacodynamic monitoring in late-stage cancer patients

Mar 08, 2016, 08:15 ET from Trovagene, Inc.

SAN DIEGO, March 8, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will be presenting at the Molecular Medicine Tri-Conference 2016, highlighting clinical performance of the Company's Precision Cancer Monitoring® (PCM) technology and how high sensitivity and the ability to quantitate mutational load translates into clinical applications for treating late-stage cancer patients. Vlada Melnikova, M.D., Ph.D., will deliver the presentation on March 10, 2016 at 12:15 p.m. (PST) in San Francisco, CA. The presentation, entitled Pharmacodynamic Assessment of Drug Response by Monitoring Mutational Load in Urinary Circulating Tumor DNA, will feature data from clinical studies in both lung and pancreatic cancer.

"We believe that the superb clinical performance of our technology platform provides competitive advantages and enables medically relevant applications of our non-invasive cancer monitoring assays using circulating tumor DNA," stated Antonius Schuh, Ph.D., chief executive officer of Trovagene. "Our presentation at the Molecular Medicine Tri-Conference will illustrate some of these applications and the ability to generate clinically actionable information to assist physicians in the personalized treatment of cancer patients."

Slides from the presentation will be made available on Trovagene's website at http://trovagene.investorroom.com/events after the presentation has been delivered at the conference.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene's precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Trovagene's expectations, strategy, plans or intentions. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition;  our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our technologies or products will provide competitive advantages, be utilized by physicians or other service providers, prove to be commercially successful or assist in the treatment of cancer patients. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2014 and other periodic reports filed with the Securities and Exchange Commission.

Contact

Investor Relations

Media Relations

David Moskowitz and Amy Caterina

Investor Relations

Jody LoMenzo

Corporate Practice Counsel

Trovagene, Inc.

Inventiv Health Public Relations

858-952-7593

212-364-0458

ir@trovagene.com

Jody.LoMenzo@inventivhealth.com

Logo - http://photos.prnewswire.com/prnh/20160307/341496LOGO

 

SOURCE Trovagene, Inc.



RELATED LINKS

http://www.trovagene.com